Showing results (1631-1640 of 2,288) with videos related to

Sort By:
Pageof 229
HIV Medicine|November 8, 2022
Late diagnosis of HIV: An updated consensus definitionSara Croxford, Annemarie Rinder Stengaard, Johanna Brännström, et al.
HIV Medicine|December 10, 2025
Towards inclusive HIV cure development: Identifying important and acceptable HIV cure attributes and strategies among people with HIV in the NetherlandsMaaike A J Noorman, John B F de Wit, Tamika A Marcos, et al.
HIV Medicine|December 1, 2025
HIV PrEP use and unmet need among gay, bisexual and other men who have sex with men in London: An analysis of community cross-sectional surveys in England 2019-2022Flavien Coukan, Dana Ogaz, John Saunders, et al.
HIV Medicine|December 1, 2025
User-reported outcomes of long-acting injectable PrEP with Cabotegravir: Real-world experience from MilanAngelo Roberto Raccagni, Flavia Passini, Riccardo Lolatto, et al.
HIV Medicine|January 28, 2026
Hierarchical analysis of unsuccessful tuberculosis treatment among people living with HIV in Brazil using nationwide surveillance dataLucas Vinícius de Lima, Gabriel Pavinati, Francisco Beraldi-Magalhães, et al.
HIV Medicine|November 25, 2025
Cardiovascular disease in people living with HIV in Malaysia: A competing risks cohort analysisHoon Shien Teh, Kim Heng Tay, Yvonne Mei Fong Lim, et al.
HIV Medicine|November 21, 2025
Comprehensive geriatric assessment for people living with HIV and frailty: A mixed-methods feasibility randomized controlled trialNatalie St Clair-Sullivan, Katherine Bristowe, Stephen Bremner, et al.
HIV Medicine|January 6, 2026
Long-term immune reconstitution patterns and influencing factors in people living with HIV exhibiting suboptimal immune response after 24 months of antiretroviral therapyLiting Yan, Qing Xiao, Lin Tuo, et al.
HIV Medicine|December 23, 2025
Cannabis use, microbial diversity and Dialister abundance in older adults with HIV: A cross-sectional studyDonald D Porchia, Yan Wang, Zhi Zhou, et al.
HIV Medicine|December 12, 2025
Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE studyM Gartland, X Wang, Q Liao, et al.
Pageof 229